Nov 9, 2021 Amylyx Pharmaceuticals Announces Results from PEGASUS Trial of AMX0035 in Alzheimer’s Disease at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference Nov 4, 2021 Amylyx Pharmaceuticals Announces Participants Dosed in the Global Phase 3 PHOENIX Study of AMX0035 in ALS Nov 2...